In Section C, contributors will receive ABBV-744 and oral navitoclax. In Phase D, participants will get ABBV-744 and ruxolitinib. Members will get treatment until eventually illness progression or even the individuals are not able to tolerate the study drugs. - Participant eaten grapefruit or grapefruit items within three times ahead https://abbv-744-clinical-trial-p24680.blogginaway.com/32548586/about-abbv-744-in-clinical-trials-for-non-small-cell-lung-cancer-nsclc